Analyst: This Pharma Stock Could Triple

The brokerage firm also initiated coverage with an "outperform" rating

by Karee Venema

Published on Dec 7, 2018 at 10:35 AM

RBC initiated coverage on Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) with an "outperform" rating and $23 price target -- a 245% premium to last night's close. The analyst in coverage waxed optimistic over the long-term upside potential of the drugmaker's lead drug lenabasum, which is currently undergoing trials in patients with cystic fibrosis and systemic sclerosis.

In response, CRBP is trading up 5.8% at $7.05. The shares shot nearly 54% higher back on Sept. 20, on the back of a well-received licensing deal, but have since been stuck beneath a trendline connecting lower highs from early October. Today's pop has the shares aiming for a close in positive year-to-date territory, having entered 2018 trading at $7.10.

crbp stock daily price chart on dec 7

Analysts have remained upbeat on the shares, with 100% of those in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target sits all the way up at $23.33.

Short sellers, on the other hand, have been actively targeting CRBP stock. Short interest on the pharma name is up almost 82% since the start of the year, to 14.12 million shares, and hit a record high 14.53 million shares in the Nov. 1 reporting period. The current number of shorted shares accounts for 26.3% of the equity's available float, or 15 times the average daily pace of trading.

a schaeffer's exclusive

5 HOT STOCK PICKS

Heat up your summer trading with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Choosing the Right Online Broker
Click to continue to advertiser's site.
Deutsche Bank Hits New Lows Amid NYT Accusations, Analyst Downgrade
A New York Times report accused the bank of not reporting suspicious activity from the U.S. President and his son-in-law
Morgan Stanley Bullish on Target Stock Ahead of Earnings
Target will report earnings on Wednesday, May 22, before the open
Choosing the Right Online Broker
Click to continue to advertiser's site.